License and Collaboration Agreements - Schedule of Payments Allocated to Performance Obligations (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($)
Allocation of transaction price
Upfront cash payment	$ 175,000
Payment for access rights related to the Company's research and development pipeline	99,126
Premium from Stock Purchase Agreement	90,600
Total transaction price allocated to revenue	364,726
Allocation to performance obligations
Zimberelimab license	55,096
Etrumadenant option	126,657
Domvanalimab option	36,640
Access rights related to the Company's research and development pipeline	136,653
Development and commercialization services for zimberelimab	9,680
Total	$ 364,726